Last reviewed · How we verify
Triaxis, Sanofi Pasteur — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Triaxis, Sanofi Pasteur (Triaxis, Sanofi Pasteur) — Elke Leuridan, MD, PhD.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Triaxis, Sanofi Pasteur TARGET | Triaxis, Sanofi Pasteur | Elke Leuridan, MD, PhD | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Triaxis, Sanofi Pasteur CI watch — RSS
- Triaxis, Sanofi Pasteur CI watch — Atom
- Triaxis, Sanofi Pasteur CI watch — JSON
- Triaxis, Sanofi Pasteur alone — RSS
Cite this brief
Drug Landscape (2026). Triaxis, Sanofi Pasteur — Competitive Intelligence Brief. https://druglandscape.com/ci/triaxis-sanofi-pasteur. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab